$THRX: Theseus Pharmaceuticals, Inc. - Common Stock

Theseus Pharmaceuticals, Inc. (THRX) is a clinical-stage biopharmaceutical company developing novel oncology therapies to address treatment-resistant cancer mutations. The company's lead product candidate, THE-630, is an investigational drug targeting a specific type of cancer-causing mutation called KRAS-G12C. THE-630 is currently in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors with KRAS-G12C mutations.

Here are some of the key things to know about THRX:

• Pipeline: THE-630 is the company's lead product candidate, but it also has a pipeline of other preclinical development programs.
• Competition: THRX faces competition from other companies developing KRAS-G12C inhibitors, such as Amgen (AMGN), Mirati Therapeutics (MRTX), and Roche (RHHBY).
• Market opportunity: The market for KRAS-G12C inhibitors is estimated to be worth billions of dollars per year.

Overall, THRX is a high-risk, high-reward investment. The company's lead product candidate has the potential to be a blockbuster drug, but it is still in early-stage clinical development. THRX also faces significant competition from other companies developing KRAS-G12C inhibitors.